"Here, your appearance can be rejuvenated; here, your failing organs can be re-cloned; here, your life can be extended..."
Tianqing Shares (832035, OC), this stem cell company in Harbin, Heilongjiang Province A storage application company listed on the New Third Board declared: "Here, mankind's millennium dream is being realized." Such exaggerated publicity has even attracted patients, including retired doctors, to receive stem cell treatment.
The gate of Tianqing Co., Ltd. Photographed by Hua Ang, an intern reporter
Recently, a reporter from the Daily Economic News (WeChat ID: nbdnews) went to Harbin to investigate and found that hospitals affiliated with Tianqing Co., Ltd. charge a high price for stem cell treatment services.
According to relevant national policies, there are currently only 102 tertiary hospitals in the country as national stem cell clinical research registration units, which are allowed to conduct clinical research and are not allowed to charge fees to subjects. Neither Tianqing nor its affiliated hospitals are qualified to conduct clinical research on stem cells.
The company claims to treat diabetes thousand cases
Stem cells are a type of cells with self-renewal and multi-differentiation potential, and are widely used in research fields such as regenerative medicine, cell replacement therapy and drug screening. Currently, many domestic and foreign pharmaceutical companies are actively exploring the development of stem cell drugs.
Image source: Visual China (pictures and texts are irrelevant)
Tianqing Shares introduces the latest achievements in the field of stem cell treatment at home and abroad in the form of popular science on its official website, which claims that stem cells can treat diabetes.
Daily Economic News (WeChat ID: nbdnews) reporter asked Tianqing Co., Ltd. as a relative of a type 2 diabetes patient whether it can provide stem cell treatment services. The company staff responded: "Umbilical cord mesenchymal stem cells, this is what our family does. "The volume of this is quite large." He also assured reporters: "You don't have to worry about quality. We are the only stem cell bank in our province (Heilongjiang), and we do a lot of this externally."
" From me. There are probably thousands of cases, because there are too many cases of type 2 diabetes. ”
Tianqing shares claim to use intravenous injection to reinfuse stem cells for patients. Normally, patients need four stem cell reinfusions to complete a course of treatment. If you lose, it can also be compressed to three times. As for the price of , "the minimum price is 60,000 yuan."
In July 2015, the former National Health and Family Planning Commission and the former State Food and Drug Administration jointly issued the "Stem Cell Clinical Research Management Measures (Trial)", which stipulates that medical institutions are the responsible entities for stem cell preparations and clinical research. Subsequently, two batches of 102 tertiary hospitals across the country were approved to carry out stem cell clinical research through registration.
But when the reporter asked the Tianqing staff which cooperative hospital they should go to for treatment, the answer they got was unexpected. "No, just come to our Tianqing Stem Cell Bank." The staff member said that he could first receive patients to visit the company's stem cell bank to understand the company's size. In addition to type 2 diabetes, diseases including compensated liver cirrhosis, cerebral infarction cerebral hemorrhage sequelae , systemic lupus erythematosus and other diseases can all be treated by injection of stem cells.
Can the same type of stem cells be injected to treat so many diseases? "Umbilical cord mesenchymal stem cells are so powerful!" The staff member was very confident and invited reporters to visit Harbin.
Related hospital routines are deep
The address provided by the above-mentioned staff to reporters is the Heilongjiang Renren Precision Cancer Hospital located in Songbei District, Harbin, not the corporate location of Tianqing Co., Ltd.
During the reporter's visit, there were no patients in the lobby of the hospital's outpatient building. There was only one nurse on duty at the consultation desk. Various roll-up medical advertisements were displayed in the empty lobby. The staff of Tianqing Shares, who had had previous contact, made an appointment with the reporter to have a detailed discussion in the vice president’s office. According to the guidance nurse in the lobby, the Tianqing staff member who invited reporters to the hospital is also the vice president of the hospital. " we are a (family), and the chairman is the same. " said the guiding nurse.
How could the same person claim to be an employee of a company listed on the National Equities Exchange and Quotations on the National Equities Exchange and Quotations and also be the vice president of Heilongjiang Renren Precision Cancer Hospital? In fact, Heilongjiang Renren Precision Cancer Hospital is an affiliated company of Tianqing Co., Ltd.
The National Enterprise Credit Information Publicity System shows that the actual controller of Heilongjiang Renren Precision Cancer Hospital Co., Ltd. (hereinafter referred to as Heilongjiang Renren Precision Cancer Hospital) is Liu Ming, a natural person, who holds 90% of the hospital's shares through a three-tier relationship. At the same time, Harbin Tiandi Investment Management Center (General Partnership), the controlling shareholder of Tianqing, also has an equity holder named Liu Ming. In the Tianyancha system, the two "Liu Ming" are considered one subject, and the partners, including Liu Ming, unanimously agreed to authorize the shareholder rights of Tianqing shares held by the partnership to Liu Yanqing free of charge.
Image source: Visual China (pictures and texts are irrelevant)
In addition, Harbin Jinsheng Health Biotechnology Co., Ltd. is a shareholder of Heilongjiang Renren Precision Cancer Hospital, and the former is Harbin Tiandiren Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Tiandiren Company) a wholly-owned subsidiary. According to the public transfer instructions of Tianqing Co., Ltd. when it was listed on the New Third Board, Tiandiren Company is the basis for the fortune of Liu Yanqing, the actual controller of Tianqing Co., Ltd., the current chairman and legal representative of the company.
Before going into business, Liu Yanqing was a reporter for Heilongjiang Province's "Family Health News". In October 1994, Liu Yanqing resigned from his position as a reporter. From the next month to May 2014, he served as the chairman and legal representative of Tiandiren Company. In November 2007, Tiandiren Company acquired all the shares of Harbin Tianqing Biotechnology Application Co., Ltd., the predecessor of Tianqing Shares, and held 100% of the shares of Tianqing Shares until June 19, 2014.
It is worth noting that Tianyi Pharmaceutical, the indirect holding company of Tianqing's predecessor, was investigated and punished by the U.S. Securities and Exchange Commission (SEC) and the U.S. court for financial fraud during its listing on the U.S. stock market, and was even forced to cancel its stocks. As the CEO of Tianyi Pharmaceutical, Liu Yanqing was also sentenced to be permanently banned from serving as an executive or director of any U.S. Securities and Exchange Commission (SEC) securities issuer.
Relying on its own affiliated hospitals, Tianqing's stem cell business is packaged as a "cure for difficult and complicated diseases." The vice president of the above-mentioned hospital provided reporters with a product manual of Tianqing Co., Ltd., which contains detailed principles and cases of stem cells in the treatment of various diseases.
reporters combed through the product manual and found that is used in diseases including rheumatoid arthritis, lupus erythematosus, various types of diabetes and complications, Parkinson's disease and even infertility and male erectile dysfunction (ED). Across 17 diseases, the company has listed a total of 483 patient cases in its treatment cases, and claimed that most of them had very good effects or even fully recovered.
In the case introduction, Tianqing Shares’ brochure was very detailed, such as “The patient, female, 75 years old, suffered from fatty liver due to... and later underwent stem cell transplantation under the guidance of a professional physician. One week later... a course of treatment. After that... completely returned to normal. "
On the company's official website, Tianqing shares stated that it has formed a research and development alliance with top domestic universities, including Shanghai Tongji University School of Medicine and Harbin Medical University Affiliated Fourth. Hospital etc. The vice president of Heilongjiang Renren Precision Cancer Hospital also mentioned that the company also cooperates with the Third Affiliated Hospital of Harbin Medical University (Heilongjiang Provincial Cancer Hospital).
However, reporters visited the Third and Fourth Affiliated Hospitals of Harbin Medical University respectively to ask whether they had any cooperation with Tianqing in the field of stem cell biotherapy, and received negative responses. Staff from the administrative office of Shanghai Tongji University School of Medicine also told reporters that they had no scientific research cooperation with Tianqing. A reporter from
visited the Heilongjiang Provincial Health Commission and reported to it the paid stem cell treatment services provided by hospitals affiliated with Tianqing Co., Ltd. "It is very clear that there are only two (the First and Second Affiliated Hospitals of Harbin Medical University), and (stem cell clinical research) regulations prohibit charges. If the situation you mentioned actually happened, there must be a problem." A staff member of the Heilongjiang Provincial Health Commission said, "We have always been cautious about stem cells. "
Subsequently, the reporter also called Tianqing Shares and sent an interview letter to it, trying to ask whether Heilongjiang Renren Precision Cancer Hospital is a related party of the company and whether the company has carried out stem cell treatment business. Tianqing Shares responded by email: "We Official documents will be arranged for answers later, so stay tuned. "But as of press time, the reporter has not received the official document.
Daily Economic News
